Showing results (41-50 of 103) with videos related to
Sort By:
Pageof 11
American Journal of Clinical Oncology|July 1, 2009
Hormone receptor expression is associated with a unique pattern of metastatic spread and increased survival among HER2-overexpressing breast cancer patientsShani Paluch-Shimon, Noa Ben-Baruch, Ido Wolf, et al.Journal of Neuro-Oncology|June 28, 2011
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastasesNancy U Lin, Wolfgang Eierman, Richard Greil, et al.Acta Oncologica (Stockholm, Sweden)|July 9, 2008
High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancerShani Paluch-Shimon, Ido Wolf, Hadassah Goldberg, et al.Plos One|July 23, 2013
Phase II study of concurrent capecitabine and external beam radiotherapy for pain control of bone metastases of breast cancer originYulia Kundel, Nicola J Nasser, Ofer Purim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM studyBella Kaufman, John R Mackey, Michael R Clemens, et al.Breast Cancer Research and Treatment|April 27, 2016
Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriersShani Paluch-Shimon, Eitan Friedman, Raanan Berger, et al.Breast (Edinburgh, Scotland)|May 26, 2018
Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohortTal Sella, Einav Nili Gal Yam, Keren Levanon, et al.Molecular Systems Biology|September 22, 2020
Proteomic patterns associated with response to breast cancer neoadjuvant treatmentAnjana Shenoy, Nishanth Belugali Nataraj, Gili Perry, et al.The Lancet. Oncology|January 15, 2013
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trialIstvan Lang, Thomas Brodowicz, Larisa Ryvo, et al.BMC Genomics|June 1, 2018
mRNA-seq whole transcriptome profiling of fresh frozen versus archived fixed tissuesNoa Bossel Ben-Moshe, Shlomit Gilad, Gili Perry, et al.Pageof 11